Recommendation of the President – Erwinase (crysantaspase)

On 28 March 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 35/2025 on the appraisal of the drug Erwinase (crysantaspase) for the treatment of pediatric patients with acute lymphoblastic leukemia who are hypersensitive (clinical allergy or “silent inactivation”) to pegylated asparaginase derived from E. coli

Publication in Public Information Bulletin (BIP) >>